Abstract
Aim: Kallikrein-related peptidases (KLKs) are a subgroup of serine proteases which consists of 15 genes located on the 19th (19q13.3-4) chromosome. Previous studies have shown that kallikrein-related peptidases (KLKs) associated with a variety of cancer types. However, few studies have investigated the role of KLKs in diagnosis and prognosis in intracranial tumors. Therefore, this study aimed to determine expression level changes of KLK5, KLK6 and KLK7 in intracranial tumors.
 Materials and methods: Meningioma grade I (n=15) and glioblastoma multiforme (n=15) tumor samples were examined for KLK5, KLK6 and KLK7 mRNA gene expression using reverse transcriptase polymerase chain reaction (RT-PCR). Their protein expression were determined using Western blotting.
 Results: KLK5 and KLK7 mRNAs and proteins are expressed more frequently in meningioma group whereas KLK6 mRNA and proteins are expressed more frequently in glioblastoma group.
 Conclusion: To conclude, when meningioma and glioblastoma groups were compared, it was found that there were differences in mRNA and protein expression levels of KLK5, KLK6 and KLK7. These genes may have a potential as a new biomarker for diagnosis in intracranial tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
